Chronotherapy in Hematological Malignancies: Evaluating the Rationale and Evidence

Area of Science:

• Hematological oncology
• Chronobiology
• Precision Medicine

Background:

• Hematological malignancies are a major cause of death despite advanced treatments.
• Treatment success and toxicity are influenced by the timing relative to the patient's circadian rhythm.
• Circadian clock disruption is linked to cancer development, treatment resistance, and toxicity.

Purpose of the Study:

• To review the role of circadian regulation in blood cancers.
• To explore the preclinical and clinical evidence for chronotherapy in hematological malignancies.
• To discuss challenges and future directions for time-aware cancer treatments.

Main Methods:

• Narrative review of current literature.
• Synthesis of mechanistic, preclinical, and clinical data.
• Examination of practical challenges and emerging technologies.

Main Results:

• Circadian rhythms regulate key processes in hematopoietic and immune systems.
• Disrupted circadian clocks can promote cancer and reduce treatment efficacy.
• Limited clinical data suggest treatment timing impacts outcomes in leukemia, lymphoma, and transplantation.

Conclusions:

• Chronotherapy holds promise for personalized medicine in hematological oncology.
• Further prospective studies with validated biomarkers are needed to define clinical value.
• Integrating temporal precision may enhance current therapeutic strategies.